[1] LEUNG M Y, POLLACK L M, COLDITZ G A, et al. Life years lost and lifetime health care expenditures associated with diabetes in the U.S., National Health Interview Survey, 1997-2000[J]. Diabetes Care, 2015, 38(3): 460-468.
[2] 中华医学会糖尿病学分会.中国 2 型糖尿病防治指南(2013 年版)[J].中国医学前沿杂志:电子版,2015, 7(3):26-89.
[3] BRIASOULIS A, DHAYBI O A, BAKRIS G L. SGLT2 inhibitors and mechanisms of hypertension[J]. Curr Cardiol Rep, 2018, 20(1): 1.
[4] ZINMAN B, WANNER C, LACHIN J M, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J]. N Engl J Med, 2015, 373(22): 2117-2128.
[5] MIAO Z, NUCCI G, AMIN N, et al. Pharmacokinetics, metabolism, and excretion of the antidiabetic agent ertugliflozin (PF-04971729) in healthy male subjects[J]. Drug Metab Dispos, 2013, 41(2): 445-456.
[6] WANG X X, LEVI J, LUO Y, et al. SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 protein expression is increased in human diabetic nephropathy: SGLT2 inhibition decreases renal lipid accumulation, inflammation and the development of nephropathy in diabetic mice[J]. J Biol Chem, 2017, 292(13): 5335-5348.
[7] DARDI I, KOUVATSOS T, JABBOUR S A. SGLT2 inhibitors[J]. Biochem Pharmacol, 2016, 101: 27-39.
[8] MAZIDI M, REZAIE P, GAO H K, et al. Effect of sodium-glucose cotransport-2 inhibitors on blood pressure in people with type 2 diabetes mellitus: a systematic review and meta-analysis of 43 randomized control trials with 22 528 patients[J]. J Am Heart Assoc, 2017, 6(6):e004007.
[9] WEBER M A, MANSFIELD T A, CAIN V A, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study[J]. Lancet Diabetes Endocrinol, 2016, 4(3): 211-220.
[10] YALE J F, BAKRIS G, CARIOU B, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease[J]. Diabetes Obes Metab, 2013, 15(5): 463-473.
[11] NAUCK M A. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes[J]. Drug Des Devel Ther, 2014, 8: 1335-1380.
[12] 刘圆, 孟浩宇,杨志健. 钠-葡萄糖协同转运蛋白2抑制剂在心力衰竭治疗中的研究进展[J].中国心血管杂志, 2019, 24(1): 86-88.
[13] 包丽雯, 刘荣宸, 严芳英,等.钠-葡萄糖共转运体2抑制剂治疗心血管疾病的研究进展[J].中华心血管病杂志, 2020, 48(4): 339-343.
[14] SHA S, POLIDORI D, HEISE T, et al. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus[J]. Diabetes Obes Metab, 2014, 16(11): 1087-1095.
[15] KIMMERLY D S, SHOEMAKER J K. Hypovolemia and neurovascular control during orthostatic stress[J]. Am J Physiol Heart Circ Physiol, 2002, 282(2): H645-H655.
[16] JORDAN J, TANK J, HEUSSER K, et al. The effect of empagliflozin on muscle sympathetic nerve activity in patients with type II diabetes mellitus[J]. J Am Soc Hypertens, 2017, 11(9): 604-612.
[17] ZHANG N, FENG B, MA X, et al. Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction[J]. Cardiovasc Diabetol, 2019, 18(1): 107.
[18] TERAMI N, OGAWA D, TACHIBANA H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice[J]. PLoS One, 2014, 9(6): e100777.
[19] SHIN S J, CHUNG S, KIM S J, et al. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes[J]. PLoS One, 2016, 11(11): e0165703.
[20] KAWATA T, IIZUKA T, IEMITSU K, et al. Ipragliflozin improves glycemic control and decreases body fat in patients with type 2 diabetes mellitus[J]. J Clin Med Res, 2017, 9(7): 586-595.
[21] BOLINDER J, LJUNGGREN Ö, JOHANSSON L, et al. Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin[J]. Diabetes Obes Metab, 2014, 16(2): 159-169.
[22] CHERNEY D Z, PERKINS B A, SOLEYMANLOU N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus[J]. Cardiovasc Diabetol, 2014, 13: 28.
[23] HAN J H, OH T J, LEE G, et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE (-/-) mice fed a western diet[J]. Diabetologia, 2017, 60(2): 364-376. |
